One sign of the coming of a new year in the biotechnology sector is the annual release of Steven Burrill’s Biotech Outlook, which augurs the world of biotechnology for the upcoming year. BioCommerce Week caught up with Burrill, the CEO of San Francisco-based private equity firm Burrill & Co., which manages some $500 million in investment funds, to look at the emerging systems biology marketplace.

What is your outlook for ‘05?

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.